About Fluzone Vaccine
Fluzone vaccine is produced by the world's leading manufacturer of influenza vaccines, Sanofi Pasteur. Sanofi Pasteur produces approximately 40 percent of the influenza vaccines distributed worldwide, and in the U.S. Fluzone vaccine accounts for more than 45 percent of the influenza vaccines distributed each year. Fluzone vaccine has been produced for nearly four decades and Sanofi Pasteur has provided an unmatched record of reliability and service to health-care providers.
Sanofi Pasteur is committed to raising immunization rates and improving global access to vaccines. As part of this commitment, the company has expanded its influenza vaccine production capacity in the U.S. A new U.S. influenza vaccine production facility was licensed by the FDA earlier this year and contributed to the production of Fluzone vaccine for the 2009-2010 season. In addition, Sanofi Pasteur has new formulation and filling capacity in the U.S. that enables the company to increase the amount of no preservative influenza vaccine it supplies. A Fluzone vaccine formulation (trade name: Fluzone((R)), Influenza Virus Vaccine, No Preservative) that does not contain a preservative at any stage in the manufacturing process was introduced in 2004-2005. It is the first FDA-licensed injectable influenza vaccine to be manufactured in this way. Fluzone vaccine also is the only influenza vaccine licensed for children as young as 6 months of age with a 0.25 mL pediatric dose for children 6 months through 35 months of age.
Sanofi Pasteur has a robust research and development program for both seasonal and pandemic influenza vaccines and the company is actively conducting research
|SOURCE Sanofi Pasteur|
Copyright©2009 PR Newswire.
All rights reserved